ImmuPharma (LON:IMM) Stock Price Up 28.8% - Still a Buy?

Key Points

• ImmuPharma's stock surged by 28.8% during mid-day trading, reaching a high of GBX 15.23 ($0.21), significantly up from its previous close at GBX 10.85 ($0.15).
• The company has a market capitalization of £69.86 million and a notably high PE ratio of -1,570.67, indicating potential challenges in profitability.
• ImmuPharma's lead program, Lupuzor™, aims to treat Lupus and has shown potential therapeutic activity for other autoimmune diseases, highlighting the company's focus on peptide-based therapeutics.

ImmuPharma plc (LON:IMM - Get Free Report)'s stock price rose 28.8% during mid-day trading on Saturday . The stock traded as high as GBX 15.23 ($0.21) and last traded at GBX 13.98 ($0.19). Approximately 44,749,293 shares were traded during trading, an increase of 451% from the average daily volume of 8,119,573 shares. The stock had previously closed at GBX 10.85 ($0.15).

ImmuPharma Stock Up 28.8%

The company has a market cap of £69.86 million, a PE ratio of -1,570.67 and a beta of 1.53. The company has a 50-day moving average of GBX 3.12 and a 200-day moving average of GBX 2.92.

ImmuPharma (LON:IMM - Get Free Report) last announced its earnings results on Wednesday, August 6th. The company reported GBX (0.38) earnings per share (EPS) for the quarter. ImmuPharma had a net margin of 3,519.56% and a negative return on equity of 131.41%. As a group, equities analysts predict that ImmuPharma plc will post -339.0000022 EPS for the current year.

About ImmuPharma

ImmuPharma PLC LSE AIM: IMM is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.